Antengene Corporation Limited (HK:6996) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Antengene Corporation Limited has received approval from South Korea’s Ministry of Food and Drug Safety for a supplemental New Drug Application for XPOVIO, marking its third indication. This approval allows the use of XPOVIO in combination with other drugs to treat multiple myeloma, further strengthening Antengene’s position in the global biopharmaceutical market. The company is known for its innovative treatments targeting hematologic malignancies and solid tumors.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.